Pulmonary LAM: although everolimus is not FDA-approved for the treatment of pulmonary LAM, it has been used off-label in patients who do not tolerate sirolimus
Demonstrated to improve FEV1 and 6-minute walk distance [MEDLINE]
Lymphangioleiomyomas: everolimus has been shown to have benefit, with resolution of tumors [MEDLINE]
Mechanistic Target of Rapamycin (mTOR) Inhibitor (see Mechanistic Target of Rapamycin Inhibitors, [[Mechanistic Target of Rapamycin Inhibitors]]): unlike tacrolimus, everolimus is not a calcineurin inhibitor
Antiproliferative Properties
Immunosuppressive Properties
Metabolism
xxx
Administration
xxx
Dose Adjustment
Hepatic
Renal
Adverse Effects
Cardiovascular Adverse Effects
Congestive Heart Failure (CHF) (see xxxx, [[xxxx]])
xxx
Infectious Adverse Effects
Increased Risk of Pneumocystis Jirovecii (see xxxx, [[xxxx]]) [MEDLINE]
Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363:1801-11 [MEDLINE]
Everolimus treatment of abdominal lymphangioleiomyoma in five women with sporadic lymphangioleiomyomatosis. Med J Aust. 2013 Jul;199(2):121-3 [MEDLINE]
Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study. Eur Respir J. 2015 Sep;46(3):783-94. Epub 2015 Jun 25 [MEDLINE]
mTOR treatment in lymphangioleiomyomatosis. Expert Rev Respir Med. 2016 Feb 4 [MEDLINE]